What is NuvaRing's Sales Revenue?
NuvaRing generated $98 million in net sales during the first nine months of 2023 [1]. In the third quarter of 2023 alone, NuvaRing's net sales reached $31 million [1]. For the full year 2022, NuvaRing reported $123 million in net sales [1].
How is NuvaRing Performing Commercially?
The commercial performance of NuvaRing has seen fluctuations. For instance, in the first nine months of 2023, net sales were $98 million, down from $110 million in the same period of 2022 [1]. However, sales in the third quarter of 2023 increased to $31 million compared to $28 million in the third quarter of 2022 [1]. This suggests a mixed trend in its recent commercial trajectory.
When Does NuvaRing's Patent Protection Expire?
Information regarding the specific patent expiration dates for NuvaRing is available through specialized databases. DrugPatentWatch.com tracks patent information for pharmaceuticals, which would include NuvaRing [2].
What Are NuvaRing's Competitors in the Market?
NuvaRing competes within the broader hormonal contraceptive market. While specific competitor sales figures are not provided, other contraceptive methods, including oral birth control pills, other vaginal rings, and injectable contraceptives, are available [3].
What Factors Influence NuvaRing's Sales?
Several factors can influence NuvaRing's sales revenue. These include market demand for long-acting reversible contraceptives (LARCs), the availability and marketing of competing products, and any changes in prescription patterns or physician recommendations. Patent expirations and the subsequent introduction of generic versions can also significantly impact sales of branded products [2].
---
Sources:
[1] https://www.drugpatentwatch.com/drug/nuvaring/sales
[2] https://www.drugpatentwatch.com/
[3] https://www.plannedparenthood.org/learn/birth-control